

CF-AIR & CF@LANTA NEWSLETTER

Cystic Fibrosis Center of Excellence


Emory University - Children's Healthcare of Atlanta -
Georgia Tech - Augusta Univ. - Georgia State - UGA



DECEMBER 2025



Director's Update Dr. Nael McCarty



Dear colleagues and friends of CF@LANTA,

We hope this finds you well, as we share the latest news. As you'll see in the following pages, CF@LANTA faculty, staff, and trainees were very well-represented at the recent North American CF Conference (NACFC) in Seattle. We presented lots of science, and made great connections. Please see the list of presentations from our CF-AIR, CF@LANTA and affiliate members [here](#). In addition, you can find the complete posting of NACFC talks [here](#).

We are excited to share that Atlanta will host the 2026 NACFC meeting. There will be lots of opportunities for patients and families to participate, and for all of us to learn about the latest advances in CF research and care. Please note that we will have a special gathering on Tuesday night, October 6, to celebrate all that our center has accomplished. That same day, CF@LANTA will be hosting the first-ever "CF Data Science Workshop" near the conference venue. We will share details soon.

Finally, I want to take a moment to point out our very own Dr. Clovis Sarmiento, who just this month received the "2025 Outstanding Care Center Partnership Award" from the GA Chapter of the CFF. Clovis has served with distinction as the liaison between CF@LANTA and the GA Chapter, and we are very grateful for his work. Thanks, Clovis!

Remember that if you are new to our newsletter, you may access past issues on our website: www.cfatl.org.

With gratitude and best wishes,
Nael



In This Issue

2-3 NACFC 2025

4 Events & Updates

5 Research Highlight

6 Researcher Spotlight

7 Recent News

8-9 Publications List

10 Seminar Schedule


11 Connect with Us

NACFC 2025: Conference Highlights

The 2025 North American Cystic Fibrosis Conference brought more than 4,000 people to Seattle, and our investigators were well represented throughout the meeting. Many served as speakers in scientific sessions, while others led discussions, presented new findings, or facilitated conversations within their specialty areas. Our faculty and partners played key leadership roles, chairing seven sessions throughout the week. These included contributions from **Dr. Ben Kopp, Dr. Kathryn Oliver, Dr. Tanicia Daley, Dr. Rachel Linnemann, Dr. Brandi Middour-Oxler, Dr. Irina Molina Miralda, and Amy Pridgen.**



CF@LANTA and CF-AIR also remained highly visible in the poster hall, presenting **62 abstracts** across basic, translational, outcomes, and clinical research. The strong presence of our teams reflected both the depth of our expertise and the collaborative environment across our programs. Readers interested in learning more about the abstracts presented at NACFC can find additional details on the [Volume 24, Supplement 2 of the Journal of Cystic Fibrosis](#).



Each day concluded with one of the conference's three plenary sessions, which helped frame major themes in the field. The first explored what has been learned from six years of highly effective modulator therapy and highlighted priorities for future progress. The second focused on the evolving needs of an aging CF population as people live longer, healthier lives. The final plenary addressed global disparities in access to care, underscoring the ongoing challenges faced by individuals in regions where diagnostic tools, specialized care, and modulators remain limited. Recordings and more information are available on the [NACFC website](#).



The global CF community played an important role throughout the week. International clinicians, researchers, and advocates shared perspectives on access, equity, and the barriers that still exist for many people living with CF around the world. Their contributions were a powerful reminder that scientific advances must reach all individuals with CF, *regardless of location or resources*.



NACFC 2025: Conference Highlights



CF@LANTA also brought colleagues together outside the scientific sessions by hosting a reception at **Flatstick Pub in South Lake Union**. Research and clinical teams from across institutions met to connect, share updates, and celebrate the accomplishments while enjoying food, drinks, and darts in a relaxed setting.



A highlight of the conference was the recognition of three CF Scholars, **Dr. Irina Miralda Molina** a Postdoctoral Fellow in the Kopp Lab at Emory, **Su Yeon Oh** (left) a PhD Candidate in the Chandler and Alvarez Lab at Emory, and **Jiafeng “Stuart” Song** a PhD Candidate in the Kamaleswaran Lab at Duke, who were selected from hundreds of submissions to compete for the Best Abstract in Basic Science Research. Dr. Miralda Molina (pictured far left with the Kopp Lab) received the award, marking an outstanding achievement for her and a proud moment for our program.



Looking ahead, we are excited that **Atlanta will host the next North American Cystic Fibrosis Conference from October 7–10, 2026**. It will be a wonderful opportunity to highlight the work happening across Georgia and to welcome the global CF community to our city.



Congratulations to the Augusta University Cystic Fibrosis Care Center

Each year, the Cystic Fibrosis Foundation honors care centers that exemplify true partnership in our mission to support people with CF and their families. The Outstanding Care Center Partnership Awards recognize care center teams who go above and beyond in collaborating with their local chapters to strengthen community engagement, promote Foundation programs, and foster meaningful connections with families. Congratulations to both the Augusta University Cystic Fibrosis Care Center - Adult & Pediatric - for receiving this award at the North American Cystic Fibrosis Conference in October 2025.

Events & Updates

Children's + Emory Care Center Winter Bipartite

The **Children's + Emory Care Center's Winter Bipartite**, held on **December 10, 2025** at the Children's Support building, provided an opportunity for clinical and research staff serving children and adult patients with cystic fibrosis to share updates and connect with each other on their current and future work. Rachel Linnemann, MD, Director of the Cystic Fibrosis Care Center at Children's and Emory, opened the session with an update on the Center. Mariela Duval, PharmD provided an overview of modulator side effects, and Kelly Ko, PharmD spoke about Brensocatib. Eric Hunter, Lead Clinical Research Coordinator, presented information on CF clinical trials for 2026, and Chris Driggers, Clinical Research Coordinator and Technical Director of the CF Discovery Core and CF Biospecimen Repository (CF-BR), discussed the Emory + Children's investigator-initiated CF research studies and patient registry. At the end of the session, Dr. Linnemann presented awards to the recipients below. A special thank you to the Georgia Chapter of the Cystic Fibrosis Foundation for providing desserts and coffee to our participants, and for their continued support of our work!

Congratulations to Children's + Emory Care Center Awardees!

Kim Williamson, BSRT, RRT

Dr. Arlene Stecenko Leadership Award for Excellence in CF Care

Karin Krikorian, BSRT, RRT, CPFT

Dr. Daniel Caplan Hero Award for Pediatric CF Care

Laura C. Anderson, BSN, RN, AMB-BC

Ms. Barbara Henry Hero Award for Adult CF Care



Pictured above, left to right: Laura Anderson, Kim Williamson and Karin Krikorian



Congratulations to **Clovis Sarmiento, MD**, for his selection as the recipient of the **2025 Outstanding Care Center Partnership Award from the Georgia Chapter of the Cystic Fibrosis Foundation**. This is awarded to a local team or member associated with a CFF care center who collaborates with the chapter staff to create meaningful engagement opportunities for our CF community.

Mark Your Calendar: CF Family Education Day



CF Family Education Day is coming up, on Saturday, January 24th from 9 am-1 pm at Arthur M. Blank Hospital and on Zoom. We are excited to announce that **David Fedele, PhD, ABPP**, will be the keynote speaker, presenting on cystic fibrosis and mental health. Dr. Fedele is Principal Research Scientist and Program Director in the Center for Healthcare Delivery Science and the Center for Pharmacogenomics and Translational Research at Nemours Children's Health.

His research in cystic fibrosis focuses on self-management, including adherence, mental health, and physical activity. His broader work explores how technology can track daily health behaviors and deliver adaptive interventions that support well-being. Dr. Fedele is also a licensed psychologist and board certified in clinical child and adolescent psychology. Please mark your calendar and **register [here!](#)**

Research Highlight

Recent Research Leads to Improvements in Newborn Screening for Cystic Fibrosis

Children's Healthcare of Atlanta + Emory faculty Rachel Linnemann, MD, Brittany Truitt, MD, and Kathryn Oliver, PhD, recently published research resulting in improvements in Georgia's statewide newborn screening (NBS) process for cystic fibrosis (CF).

In the first study, the team characterized children with CF born in Georgia who were missed by NBS or had delayed diagnosis despite positive NBS. Nearly 5% of children with CF had a false negative NBS, and most delayed diagnoses were related to challenges with sweat testing. Minoritized children made up 19% of Georgia CF births during the study period but 43% of missed and 44% of delayed diagnoses. They furthermore found that Hispanic infants had 6.1 times the odds of missed or delayed diagnosis compared to non-Hispanic White infants, while Black infants had 2.7 times higher odds of being missed or delayed. Their findings were recently published [here](#), in the *International Journal of Neonatal Screening*.

In a second related study, the team examined CF transmembrane conductance regulator (CFTR) gene variant frequencies and NBS genetic test performance for people with CF currently receiving care in Georgia. A panel including 719 CF-causing variants from the CFTR2 database would significantly improve case detection from 93% to 97%, as well as two-variant detection from 69% to 86%. Compared to Georgia's current 39 variant panel, they found that larger variant panels would improve case detection and timeliness of diagnosis due to increased detection of two gene variants. These findings were also recently published [here](#), in the *International Journal of Neonatal Screening*.

"Based on our study data, the Georgia Newborn Screening Advisory Committee recommended to the Georgia Department of Public Health the implementation of a floating immunoreactive trypsinogen (IRT) cut-off and an expanded CF transmembrane conductance regulator (CFTR) assay for CF NBS in the state," Dr. Linnemann commented. "These changes are expected to improve equity in CF newborn screening. Evaluation of the feasibility and funding required for implementation is under consideration by the Georgia Department of Public Health."

The team is also conducting a related quality improvement project to reduce delays in diagnosis due to sweat testing issues, which they presented in Quality Improvement in Action Rounds at Children's Healthcare of Atlanta on November 20, 2025. The project has resulted in a reduction in the average time from birth to sweat testing at Children's for infants with an abnormal CF newborn screen and only one variant detected from 45 days to 28 days.

Research collaborators for the studies included Augusta University, the Georgia Department of Public Health, the Georgia Public Health Laboratory, and the Emory Newborn Screening Follow-up Program.

[Dr. Linnemann](#) serves as the Director of the Cystic Fibrosis Care Center at Children's and Emory, and she is also an Associate Professor in the Department of Pediatrics at the Emory University School of Medicine.

[Dr. Truitt](#) and [Dr. Oliver](#) are Assistant Professors in the Department of Pediatrics at the Emory University School of Medicine.



“***This project has led to multiple changes at the state level in CF NBS follow-up processes, with the goal of improving timely diagnosis.***”

-Dr. Rachel Linnemann

Researcher Spotlight

Dio Kavalieratos, PhD, FAAHPM



Effective September 1, 2025, Dr. Dio Kavalieratos has been appointed the new Director of the Division of Palliative Medicine. In this role, he works to ensure that over 40 faculty members (both clinical and research) have the mentorship, infrastructure, and resources needed to thrive as scholars, educators, and leaders. He is the first non-physician to lead an academic division of palliative medicine in the United States. Dr. Kavalieratos also continues to serve as the Director of Research for the Emory Palliative Care Center, where he leads research, training, and mentoring initiatives. In addition, he serves on the Board of Directors of the American Academy of Hospice and Palliative Medicine (AAHPM), the field's premier national organization.

Current Research: Advancing Symptom Science in Cystic Fibrosis

Dr. Kavalieratos and colleagues received a \$2.4M NIH R01 (R01HL171735) to lead the PULSE-CF study: Patient-centered Understanding of Quality of Life, Symptoms, and Health Equity in Cystic Fibrosis, a partnership between Emory and Augusta University (team members include Dr. Jane Lowers, Chris Driggers, Dr. Joshua Chandler, Dr. Brandi Middour-Oxler, Dr. Arlene Stecenko, Dr. Rishi Kamaleswaran, and Dr. Anne Fitzpatrick from Emory, and Dr. Ryan Harris and Reva Crandall from Augusta). This five-year study uses cutting-edge mixed-methods research to address a fundamental gap in CF care: while CFTR modulator therapy has dramatically changed the outlook of care and life for many people living with CF, a vast majority of people living with CF (including 78% of adults on CFTR modulator therapy) report persistent symptoms (particularly fatigue, pain, and anxiety). PULSE-CF's innovative approach triangulates in-depth qualitative patient interviews with metabolomic analyses to connect biological pathways with patient-reported experiences of symptom burden and healthcare experiences. By analyzing which metabolites correspond to specific symptoms, we aim to identify biomarkers and discover therapeutic targets that address both physiologic dysfunction and patient priorities. This work represents a paradigm shift toward precision medicine in CF symptom management. The study deliberately oversamples Black and Hispanic adults with CF to address health equity gaps, as these populations have been historically underrepresented in CF research despite experiencing worse outcomes. This commitment to equity extends across his research portfolio.

Recent Clinical Trial: InSPIRe:CF

Dr. Kavalieratos' team (including Dr. Randy Hunt and Dr. Jane Lowers) recently completed the InSPIRe:CF randomized clinical trial (CFF grant KVAL21QIO, \$3.0M), which enrolled 260 adults with CF across five US and Canadian sites to test whether adding specialist palliative care to usual CF care improves quality of life.

Mentoring & Career Development

In addition, Dr. Kavalieratos currently mentors individuals across the continuum, from undergrads to mid-career faculty in research, scholarship, and professional development. This includes five mentees with NIH-funded career development awards and four additional funded faculty across pulmonary, social work, nursing, and informatics, as well as PhD students and postdocs.

Other Recent Accomplishments

- Senior author, Cystic Fibrosis Foundation Clinical Practice Guidelines on pain management (December 2024)
- >120 peer-reviewed publications, including JAMA (x2), JAMA Pediatrics, JCF, JACC: Heart Failure
- Principal Investigator, Fraser-Parker Foundation (\$1.4M): Dr. Kavalieratos led the securing of \$1.4M from a local foundation to establish the Emory Serious Illness Innovation Incubator (ESI3) to accelerate scientific discovery in palliative care by providing seed funding, methodological support, and collaborative resources for early-stage research projects.

Please join us in congratulating Dr. Kavalieratos on his new appointment and celebrating his impactful work in palliative medicine and addressing the needs of people with cystic fibrosis.

Recent News

Faculty Recognitions



Congratulations to Brian Vickery, MD on his award for “Senior Faculty Excellence in Clinical Research,” which he received at the 2025 Children’s + Emory Annual Faculty, Physician & Staff Awards Ceremony on November 19, 2025. This recognition is awarded to an Associate Professor or Professor who has played a leadership/instrumental role in the development of an innovative program/procedure in research.

Also, congratulations to Dr. Vickery on his recent grant funding for Sharing Approaches to Food Allergy that Revolutionize Improvement (SAFARI): Building Capacity for the First Food Allergy Learning Health Network, awarded by the National Peanut Board in November 2025. Emory is one of nine organizations receiving this grant, furthering food allergy research and working toward the end of peanut allergy. In addition, the SAFARI project receives the honor of the Dee Dee Darden Award, named for the Virginia peanut farmer and early National Peanut Board chair who pursued allergy research opportunities for the Board to support, leading to the early introduction guidelines for peanut allergy prevention that exist today.

The National Peanut Board notes that “Emory’s project has an inspiring vision: for every food allergy patient interaction to contribute to knowledge that benefits future patients, and for the best available evidence to be rapidly integrated into routine care and at scale. The highly rated proposal embodies the Darden spirit and showcases the potential of building bridges and increasing collaboration for maximum impact in food allergy.”

Dr. Vickery commented that this award is a “validation of the concept - and the special recognition in honor of Ms. Darden is especially motivating and suggests that the core message of the proposal landed as intended, as a collaborative and patient-centered solution to an urgent need.”



Congratulations to Dawn Simon, MD, Division Chief of Pulmonology, Asthma, Cystic Fibrosis and Sleep, for her recent promotion to Professor.



Congratulations to Kathryn Oliver, PhD, for her award for “Best Publication-Quality Improvement” at the 2025 Children’s + Emory Annual Faculty, Physician & Staff Awards Ceremony on November 19, 2025. This recognition is awarded to a faculty or physician who has made a major contribution to a quality improvement publication in a top journal. The paper, “Cystic Fibrosis Foundation Evidence-Based Guideline for the Management of CRMS/CFSPID,” has received 25,824 total views, 5,761 PDF downloads, and 23 citations.

Publications Since Our Last Newsletter



Kudos to our CF-AIR/CF@LANTA investigators

A call for the United States to continue investing in science, *ASM Case Rep*, 2025 Feb 27.

Manipulation of the nucleoscaffold potentiates cellular reprogramming kinetics, *PNAS Nexus*, 2025 Sep 25.

CFTR Variant Frequencies and Newborn Screening Panel Performance in the Diverse CF Population Receiving Care in the State of Georgia, *Int J Neonatal Screen*, 2025 Sep 26.

Evaluating Georgia's Cystic Fibrosis Newborn Screening Algorithm to Inform Improvement Recommendations, *Int J Neonatal Screen*, 2025 Sep 29.

Phenotype-Based Management of Recurrent Preschool Wheezing and Asthma, *J Allergy Clin Immunol Pract*, 2025 Oct.

Illness Burden in Adults With Cystic Fibrosis: Associations With Sex, Race/Ethnicity, and Socioeconomic Risk Factors, *Pediatr Pulmonol*, 2025 Oct.

Proposing New Criteria for Classification of Benign Fibroepithelial Lesions Based on Clinicopathologic Evaluations of 507 Cases with Clinical Outcome, *Mod Pathol*, 2025 Oct.

A Protocol Guide to Micro Milling for Bio-Microfluidics, *Bio Protoc*, 2025 Oct 5.

Sexual health experiences and care utilization of males with cystic fibrosis, *J Cyst Fibros*, 2025 Oct 6.

The versatile synthesis and biological evaluation of all-alkyl biscationic quaternary phosphonium compounds: atom-economical and potent disinfectants, *RSC Med Chem*, 2025 Oct 8.

Microfluidic Device Type Improves Heart mRNA Delivery In Vivo, *Langmuir*, 2025 Oct 14.

Single cell transcriptional profiling of monocytes from asthma patients show a predisposition for an inflammatory response, *Cytotherapy*, 2025 Oct 14.

Assessment of genetic and metabolite associations of branched chain amino acids with metabolic disease in the UK Biobank using Mendelian randomization, *BMC Med Genomics*, 2025 Oct 16.

Mapping the respiratory microbiome in intubated children over time, *Microbiol Spectr*, 2025 Oct 20.

Integrated epigenetic and genetic programming of primary human T cells, *Nat Biotechnol*, 2025 Oct 21.

Triscationic bolaamphiphilic QACs - optimizing antibacterial therapeutic indices, *Bioorg Med Chem Lett*, 2025 Oct 21.

Cancer history and cardiovascular diseases: Implications for colorectal and breast cancer screening, *J Med Screen*, 2025 Oct 22.

Discovery of Na_v1.7 Inhibitors through the Screening of Marine Natural Product Extracts, *J Nat Prod*, 2025 Oct 22.

Assessment of the metabolome across the glucose tolerance spectrum in adults with cystic fibrosis hospitalized for pulmonary exacerbations, *Respir Med*, 2025 Oct 23.

Substrate Exclusion Greenlights Physical Autocatalysis of Enzyme Activity in Membraneless Proto-Organelles, *Biomacromolecules*, 2025 Oct 29.

Using wastewater surveillance to investigate community-level differences in antibacterial resistance in a major urban center, USA, *Appl Environ Microbiol*, 2025 Oct 30.

Analysis of Teg41 and PSMα promoter activity using a divergent fluorescent reporter plasmid, *mSphere*, 2025 Oct 31.

Click to link to the publication. Full citations available at <https://cfatl.org/recent-publications>.

Publications Since Our Last Newsletter



Kudos to our CF-AIR/CF@LANTA investigators (continued)

Experimental evolution of gene essentiality in bacteria, *mBio*, 2025 Oct 31.

Metabolomic profiling of Burkholderia thailandensis infection of airway epithelial cells provides insights into potential therapeutic targets, *mSystems*, 2025 Oct 31.

"All my food is customized": Barriers & facilitators concerning nutrition for persons living with cystic fibrosis, *J Cyst Fibros*, 2025 Nov.

The state of the academic medical center in allergy/immunology: Work Group Report of the AAAAI A/I Division Directors Committee, *J Allergy Clin Immunol*, 2025 Nov.

Lipid nanoparticle-mediated mRNA delivery to CD34⁺ cells in rhesus monkeys, *Nat Biotechnol*, 2025 Nov.

Pseudomonas aeruginosa: ecology, evolution, pathogenesis and antimicrobial susceptibility, *Nat Rev Microbiol*, 2025 Nov.

Relationship between skeletal muscle indicators and clinical outcomes in cystic fibrosis is modified by adiposity and CFTR modulator use: a cross-sectional analysis, *Am J Clin Nutr*, 2025 Nov.

Symptom factors and their clinical correlates among adults with cystic fibrosis, *J Cyst Fibros*, 2025 Nov.

The effects of combined low-dose cadmium and deltamethrin on mitochondrial bioenergetics and metabolism in human lung fibroblasts, *Toxicol Rep*, 2025 Nov 4.

Substrate Exclusion Greenlights Physical Autocatalysis of Enzyme Activity in Membraneless Proto-Organelles, *Biomacromolecules*, 2025 Nov 10.

Hyperglycemia differentially affects neutrophil transmigration across cystic fibrosis and wildtype bronchial epithelia, *J Cyst Fibros*, 2025 Nov 11.

Exploratory Analyses of Predictors and Correlates of Response to Omalizumab Therapy in Patients with Multiple Food Allergies, *J Allergy Clin Immunol*, 2025 Nov 12.

Metabolomic profiling of Burkholderia thailandensis infection of airway epithelial cells provides insights into potential therapeutic targets, *mSystems*, 2025 Nov 18.

Bacterial immune systems as causes and consequences of microbiome structure, *PLoS Biol*, 2025 Nov 19.

Derivation and validation of the Pediatric Community-Acquired Pneumonia Severity (PedCAPS) score: A prospective cohort study, *J Hosp Med*, 2025 Nov 21.

Analysis of Teg41 and PSM α promoter activity using a divergent fluorescent reporter plasmid, *mSphere*, 2025 Nov 25.

Human lung CD8⁺ tissue-resident memory T cell-derived interferon- γ orchestrates subset-specific antiviral programming in airway epithelial cells, *Immunity*, 2025 Nov 26.

Staphylococcus aureus induces Gasdermin A-dependent keratinocyte pyroptosis, *Nat Commun*, 2025 Nov 26.

Assessment of the metabolome across the glucose tolerance spectrum in adults with cystic fibrosis hospitalized for pulmonary exacerbations, *Respir Med*, 2025 Nov-Dec.

AI in Palliative Care: A Scoping Review of Foundational Gaps and Future Directions for Responsible Innovation, *J Pain Symptom Manage*, 2025 Dec.

Click to link to the publication. Full citations available at <https://cfatl.org/recent-publications>.

CF-AIR Seminar Series, 2025–2026 Academic Year

SPRING 2026 SCHEDULE			
Date	Time	Type	Presenter
8-Jan	1-2 PM	Journal Club	Jonica Brown
15-Jan	1-2 PM	Guest Lecturer	Stephanie Lovinsky-Desir, MD (Columbia University)
22-Jan	1-2 PM	Trainee Focused	Laurence Boitet, PhD (UAB)
23-Jan	2-3 PM	Guest Lecturer	David Fedele, PhD, ABPP
29-Jan	1-2 PM	Research Highlight	Nael McCarty, PhD
5-Feb	1-2 PM	Guest Lecturer	Paul Kubes, PhD (U. of Calgary)
12-Feb	1-2 PM	Journal Club	Irina Miralda, PhD
19-Feb	1-2 PM	Trainee Focused	Liz McCarty and Amelia Randall
26-Feb	1-2 PM	Research Highlight	Drs. Tanicia Daley, Jessica Alvarez & Darko Stefanovski (UPenn)
5-Mar	1-2 PM	Guest Lecturer	Dr. Anupama Khare (NIH)
12-Mar	1-2 PM	Journal Club	Su Yeon Oh, MS
19-Mar	1-2 PM	Trainee Focused	Carleen Sabusap, PhD (MIT Museum)
26-Mar	1-2 PM	Research Highlight	Andrew Gewirtz, PhD (Georgia State)
2-Apr	1-2 PM	Guest Lecturer	Andrea Kelly, MD, MSCE (CHOP)
9-Apr	1-2 PM	Journal Club	Erica Browne
16-Apr	1-2 PM	Trainee Focused	Nathan Boyd, PhD (NIH)
23-Apr	1-2 PM	Research Highlight	Drs. Lisa Staimez, David Reiter & Priya Vellanki
30-Apr	1-2 PM	Social	Birthdays/Spring Potluck
7-May	1-2 PM	Guest Lecturer	Michelle Hastings, PhD (Michigan)
14-May	1-2 PM	Journal Club	JaNise Jackson, PhD
21-May	1-2 PM	Trainee Focused	Malinda Wu, MD, MSCR (Johns Hopkins)
28-May	1-2 PM	Research Highlight	Colin Swenson, MD
1-June	1-2 PM	Special Event	Joint Seminar with CCIV

Around the Research Organization



Share your Research Wows!

Researchers, please be sure to share your recent research accomplishments through our Research Wows submission form [here](#). The information you provide will be used for internal and external reporting, as well as potential news and media coverage.

FAQ's:

What type of information should I share?

- Impactful publications that have been accepted or published
- New, major grants that have been awarded
- New, major professional/service awards, distinctions, or recognitions received
- Other noteworthy research-related achievements (such as patents, IND, clinical trials, etc.)

Who will receive this information?

- Pediatric research center Program Managers and Center Directors
- Pediatric research leadership
- Marketing and communications teams

Please reach out to [Megan Stewart](#) with any questions. We look forward to hearing about your Research Wows!

Pediatric Core Services

Our core services offer the equipment, tools, and skilled professionals to make research faster and more impactful. From imaging and data analysis to clinical trial support, pediatric cores provide key resources and expert support to help researchers at every step.

Researchers, check out details about our pediatric research core services [here](#) or via the QR code. For any questions or details, please reach out to Cores Administrator, [Julie Flores](#).



Connect with CF-AIR & CF@LANTA

Visit Our Websites



[CF@LANTA](#)

[CF-AIR](#)

Join Our Listserv

Would you like to receive information about CF-AIR & CF@LANTA seminars and other news? Contact megan.stewart@emory.edu and request to be added to our listserv!



CF-AIR is now on BlueSky! Follow us and tag us [@emory-choa-cfair.bsky.social](#)

Follow and tag us on X [@EmoryCHOA_CFAIR](#) and [@CFAtlanta](#)

